Lexington, MA and Amsterdam, the Netherlands, September 26, 2016 - uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that Matt Kapusta, interim chief executive officer, will present an overview of the company’s programs and progress at the Jefferies Gene Editing/Gene Therapy Summit on Tuesday October 11th at the Jefferies Conference Center in New York City:
• Jefferies Gene Editing/ Gene Therapy Summit
Venue: Jefferies Conference Center, New York City
Presenter: Matt Kapusta, Interim Chief Executive Officer
Date and Time: Tuesday, October 11th, 2:00 p.m. EDT
In addition, the company will be available for one-on-one meetings at the conference. The presentation will be available at the “Investors” section of the uniQure website and can be accessed one hour after the conclusion of the live event through: http://www.uniqure.com/investors/shareholder-information/.
About uniQure
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
